News

iQHT Completes iQemo Migration to Microsoft Azure

After months of collaboration and technical preparation, iQHT has successfully migrated iQemo from UKFast to Microsoft Azure. This marks a major milestone in improving performance, resilience, and scalability across all supported NHS sites and private healthcare providers. This was made possible through the dedicated efforts of their clinical and technical teams alongside our own. Together we laid the foundation for future innovation.

After months of preparation and collaboration, we’re proud to announce that iQemo is now fully hosted on Microsoft Azure, completing our transition from UKFast and marking a significant milestone for iQHT and our customers.
This move represents more than just a change in infrastructure, it reflects our long-term commitment to performance, scalability, and clinical safety in Systematic Anti-Cancer Therapy (SACT) prescribing

Why We Made the Move

The migration to Azure was driven by our vision to:
  • Modernise the infrastructure underpinning the iQemo platform
  • Improve performance, scalability, reliability, and uptime for clinical users
  • Strengthen our data protection and disaster recovery capabilities
  • Enable faster rollouts and support future integrations

Azure provides the scale, flexibility, and security needed to power iQemo’s next chapter across a growing network of NHS Trusts and private healthcare customers.

A Complex but Coordinated Migration

This wasn’t a simple lift-and-shift. It was a complex, multi-phase project involving:

  • Multiple third-party vendors
  • Technical and clinical teams across various customers
  • iQHT’s internal development, infrastructure, and support teams

Each go-live required detailed planning, downtime coordination, and careful validation to ensure patient safety and data integrity. We’re incredibly grateful to everyone who played a role in delivering this work with care and precision.

Navigating Post-Migration Challenges

As with any major infrastructure change, some post-migration technical challenges did arise, including some connectivity inconsistencies during the initial transition period.

However, the cross-functional team responded quickly and worked together proactively to identify root causes, implement fixes, and restore full functionality. This responsiveness was key to maintaining clinician confidence and minimising disruption on the ground.

What This Means for iQHT Customers

Now fully hosted on Azure, iQemo users will benefit from:

  • Improved system performance and faster response times
  • Greater uptime and resilience to support clinical workflows
  • Enhanced security and compliance, aligned with NHS and ISO standards
  • Faster deployment cycles for new features and updates
  • A future-proof foundation for further innovation and integration

This migration puts us in a stronger position to scale and enhance iQemo in line with evolving needs.

What’s Next

With the migration complete, we’re now focused on:

  • 1.16.2 - A new and improved version of iQemo is in development with UAT becoming available for our customers later in the year

This migration sets the stage for a faster, more resilient, and more secure iQemo experience for every customer. With Azure as our foundation, we can continue to evolve the platform and bring new features to clinicians and patients with greater speed and confidence. We look forward to building the next chapter of innovation together.

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. The company delivers innovative Saas and standalone platforms, including iQemo – the industry-leading, end-to-end chemotherapy prescribing and management platform used by NHS and private hospitals in the UK, and a growing number of hospitals worldwide. Learn more

We’re working on an innovative future for healthcare technology

Sign up to our newsletter and stay updated with industry-leading advice, insight and more…

Thank you! Your submission has been received!
Sorry, something went wrong while submitting the form.

About iQemo

iQemo, from iQHealthTech, provides specialist chemotherapy prescribing. A complete end-to-end solution that includes predefined regimens, prescribing, scheduling and dispensing, through to chemotherapy administration and reporting. iQemo is used in NHS Trusts and private hospitals in the UK, and in a growing number of hospitals worldwide. Learn More

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. Learn more

Would you like more information about iQemo?

We'd love to discuss how iQemo could support your organisation, people and patients.

Get in touch